Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

NCT04365868 is registered in ClinicalTrials.gov with Galectin Therapeutics Inc. as lead sponsor.

NCT NCT04365868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04365868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Lead sponsor
Galectin Therapeutics Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
June 25, 2020
Completion date
April 10, 2025
Enrollment
357 (actual)
Sites
156

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, nash - nonalcoholic steatohepatitis, prevention of esophageal varices